Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9

Immunobiology

Volumn 214, Issue 6, 2009, Pages 410-421

  Intasai, Nutjeera ^a   Tragoolpua, Khajornsak ^a   Pingmuang, Prakitnavin ^a   Khunkaewla, Panida ^a,b   Moonsom, Seangdeun ^a   Kasinrerk, Watchara ^a   Lieber, André ^c   Tayapiwatana, Chatchai ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b SURANAREE UNIVERSITY OF TECHNOLOGY   (Thailand)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CD147; HeLa cells; Intrabody; ScFv antibody; T cell proliferation

Indexed keywords

BSG PROTEIN, HUMAN; CD147 ANTIGEN; GELATINASE; OKT 3; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

CELL MEMBRANE; CELL PROLIFERATION; CYTOLOGY; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANTIGENS, CD147; CELL MEMBRANE; CELL PROLIFERATION; GELATINASES; HEK293 CELLS; HELA CELLS; HUMANS; MUROMONAB-CD3; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 77951675122     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2008.12.006     Document Type: Article

References (70)

1. Alvarez R.D., Barnes M.N., Gomez-Navarro J., Wang M., Strong T.V., Arafat W., Arani R.B., Johnson M.R., Roberts B.L., Siegal G.P., Curiel D.T. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 2000, 6:3081-3087.
2. Bedzyk W.D., Weidner K.M., Denzin L.K., Johnson L.S., Hardman K.D., Pantoliano M.W., Asel E.D., Voss E.W. Immunological and structural characterization of a high affinity anti-fluorescein single-chain antibody. J. Biol. Chem. 1990, 265:18615-18620.
3. Bernt K., Liang M., Ye X., Ni S., Li Z.Y., Ye S.L., Hu F., Lieber A. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J. Virol. 2002, 76:10994-11002.
4. Beyer F., Doebis C., Busch A., Ritter T., Mhashilkar A., Marasco W.M., Laube H., Volk H.D., Seifert M. Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells - new perspectives for the generation of universal donor cells for tissue transplantation. J. Gene Med. 2004, 6:616-623.
5. Biswas C., Zhang Y., DeCastro R., Guo H., Nakamura T., Kataoka H., Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55:434-439.
6. Boehm M.K., Corper A.L., Wan T., Sohi M.K., Sutton B.J., Thornton J.D., Keep P.A., Chester K.A., Begent R.H., Perkins S.J. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem. J. 2000, 346(Pt 2):519-528.
7. Boldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J. Cell. Mol. Med. 2007, 11:54-70.
8. Boldicke T., Weber H., Mueller P.P., Barleon B., Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J. Immunol. Methods 2005, 300:146-159.
9. Bordador L.C., Li X., Toole B., Chen B., Regezi J., Zardi L., Hu Y., Ramos D.M. Expression of emmprin by oral squamous cell carcinoma. Int. J. Cancer 2000, 85:347-352.
10. Carlson C.A., Steinwaerder D.S., Stecher H., Shayakhmetov D.M., Lieber A. Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol. 2002, 346:277-292.
11. Chen X., Lin J., Kanekura T., Su J., Lin W., Xie H., Wu Y., Li J., Chen M., Chang J. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res. 2006, 66:11323-11330.
12. Chen X., Su J., Chang J., Kanekura T., Li J., Kuang Y.H., Peng S., Yang F., Lu H., Zhang J.L. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest. 2008, 1.
13. Chiampanichayakul S., Peng-In P., Khunkaewla P., Stockinger H., Kasinrerk W. CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. Immunobiology 2006, 211:167-178.
14. Doebis C., Schu S., Ladhoff J., Busch A., Beyer F., Reiser J., Nicosia R.F., Broesel S., Volk H.D., Seifert M. An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators. Cardiovasc. Res. 2006, 72:331-338.
15. Emadi S., Barkhordarian H., Wang M.S., Schulz P., Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 2007, 368:1132-1144.
16. Gabison E.E., Mourah S., Steinfels E., Yan L., Hoang-Xuan T., Watsky M.A., De Wever B., Calvo F., Mauviel A., Menashi S. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am. J. Pathol. 2005, 166:209-219.
17. Gallagher S.M., Castorino J.J., Wang D., Philp N.J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007, 67:4182-4189.
18. Goenaga A.L., Zhou Y., Legay C., Bougherara H., Huang L., Liu B., Drummond D.C., Kirpotin D.B., Auclair C., Marks J.D., Poul M.A. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol. Immunol. 2007, 44:3777-3788.
19. Gogly B., Groult N., Hornebeck W., Godeau G., Pellat B. Collagen zymography as a sensitive and specific technique for the determination of subpicogram levels of interstitial collagenase. Anal. Biochem. 1998, 255:211-216.
20. Griffin H., Elston R., Jackson D., Ansell K., Coleman M., Winter G., Doorbar J. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J. Mol. Biol. 2006, 355:360-378.
21. Hamilton S., Odili J., Wilson G.D., Kupsch J.M. Reducing renal accumulation of single-chain Fv against melanoma-associated proteoglycan by coadministration of l-lysine. Melanoma Res. 2002, 12:373-379.
22. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93:178-193.
23. Igakura T., Kadomatsu K., Taguchi O., Muramatsu H., Kaname T., Miyauchi T., Yamamura K., Arimura K., Muramatsu T. Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. Biochem. Biophys. Res. Commun. 1996, 224:33-36.
24. Intasai N., Mai S., Kasinrerk W., Tayapiwatana C. Binding of multivalent CD147 phage induces apoptosis of U937 cells. Int. Immunol. 2006, 18:1159-1169.
25. Jendreyko N., Popkov M., Rader C., Barbas C.F. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:8293-8298.
26. Kanekura T., Chen X., Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 2002, 99:520-528.
27. Kasinrerk W., Fiebiger E., Stefanova I., Baumruker T., Knapp W., Stockinger H. Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J. Immunol. 1992, 149:847-854.
28. Kasinrerk W., Tokrasinwit N., Phunpae P. CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. Immunology 1999, 96:184-192.
29. Khunkeawla P., Moonsom S., Staffler G., Kongtawelert P., Kasinrerk W. Engagement of CD147 molecule-induced cell aggregation through the activation of protein kinases and reorganization of the cytoskeleton. Immunobiology 2001, 203:659-669.
30. Kim D.J., Chung J.H., Ryu Y.S., Rhim J.H., Kim C.W., Suh Y., Chung H.K. Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas. Br. J. Cancer 2002, 87:405-413.
31. Kioi M., Seetharam S., Puri R.K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol. Cancer Ther. 2008, 7:1579-1587.
32. Koch C., Staffler G., Huttinger R., Hilgert I., Prager E., Cerny J., Steinlein P., Majdic O., Horejsi V., Stockinger H. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. Int. Immunol. 1999, 11:777-786.
33. Korn T., Nettelbeck D.M., Volkel T., Muller R., Kontermann R.E. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J. Gene Med. 2004, 6:642-651.
34. Liu F., Lu Q., Ye X., Fang C., Zhao Y., Liang M., Hu F., Lieber A., Chen H.Z. Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice. Cancer Biol. Ther. 2008, 7:448-453.
35. Liu M.Y., Han W., Ding Y.L., Zhou T.H., Tian R.Y., Yang S.L., Liu H., Gong Y. Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA. Acta Biochim. Biophys. Sin (Shanghai) 2005, 37:415-420.
36. Lynch S.M., Zhou C., Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 2008, 377:136-147.
37. Mao S., Gao C., Lo C.H., Wirsching P., Wong C.H., Janda K.D. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc. Natl. Acad. Sci. USA 1999, 96:6953-6958.
38. Messer A., McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases. BioDrugs 2006, 20:327-333.
39. Mhashilkar A.M., Doebis C., Seifert M., Busch A., Zani C., Soo Hoo J., Nagy M., Ritter T., Volk H.D., Marasco W.A. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 2002, 9:307-319.
40. Nabeshima K., Iwasaki H., Koga K., Hojo H., Suzumiya J., Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 2006, 56:359-367.
41. Nam C.H., Lobato M.N., Appert A., Drynan L.F., Tanaka T., Rabbitts T.H. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions. Oncogene 2008, 27:4962-4968.
42. Olafsen T., Tan G.J., Cheung C.W., Yazaki P.J., Park J.M., Shively J.E., Williams L.E., Raubitschek A.A., Press M.F., Wu A.M. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 2004, 17:315-323.
43. Pantoliano M.W., Bird R.E., Johnson S., Asel E.D., Dodd S.W., Wood J.F., Hardman K.D. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry 1991, 30:10117-10125.
44. Pavoni E., Flego M., Dupuis M.L., Barca S., Petronzelli F., Anastasi A.M., D'Alessio V., Pelliccia A., Vaccaro P., Monteriu G., Ascione A., De Santis R., Felici F., Cianfriglia M., Minenkova O. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. BMC Cancer 2006, 6:41.
45. Peng J.L., Wu S., Zhao X.P., Wang M., Li W.H., Shen X., Liu J., Lei P., Zhu H.F., Shen G.X. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem. Biophys. Res. Commun. 2007, 354:864-871.
46. Popkov M., Jendreyko N., McGavern D.B., Rader C., Barbas C.F. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 2005, 65:972-981.
47. Quemener C., Gabison E.E., Naimi B., Lescaille G., Bougatef F., Podgorniak M.P., Labarchede G., Lebbe C., Calvo F., Menashi S., Mourah S. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res. 2007, 67:9-15.
48. Reimers N., Zafrakas K., Assmann V., Egen C., Riethdorf L., Riethdorf S., Berger J., Ebel S., Janicke F., Sauter G., Pantel K. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 2004, 10:3422-3428.
49. Riethdorf S., Reimers N., Assmann V., Kornfeld J.W., Terracciano L., Sauter G., Pantel K. High incidence of EMMPRIN expression in human tumors. Int. J. Cancer 2006, 119:1800-1810.
50. Schreiner A., Ruonala M., Jakob V., Suthaus J., Boles E., Wouters F., Starzinski-Powitz A. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. Mol. Biol. Cell 2007, 18:1272-1281.
51. Staffler G., Szekeres A., Schutz G.J., Saemann M.D., Prager E., Zeyda M., Drbal K., Zlabinger G.J., Stulnig T.M., Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J. Immunol. 2003, 171:1707-1714.
52. Steinberger P., Andris-Widhopf J., Buhler B., Torbett B.E., Barbas C.F. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 2000, 97:805-810.
53. Stirnemann K., Romero J.F., Baldi L., Robert B., Cesson V., Besra G.S., Zauderer M., Wurm F., Corradin G., Mach J.P., Macdonald H.R., Donda A. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 2008, 118:994-1005.
54. Stockinger H. Interaction of GPI-anchored cell surface proteins and complement receptor type 3. Exp. Clin. Immunogenet. 1997, 14:5-10.
55. Sun J., Hemler M.E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001, 61:2276-2281.
56. Suzuki S., Sato M., Senoo H., Ishikawa K. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp. Cell Res. 2004, 293:259-266.
57. Tanaka T., Williams R.L., Rabbitts T.H. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. Embo J. 2007, 26:3250-3259.
58. Tang Y., Nakada M.T., Kesavan P., McCabe F., Millar H., Rafferty P., Bugelski P., Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65:3193-3199.
59. Tayapiwatana C., Chotpadiwetkul R., Kasinrerk W. A novel approach using streptavidin magnetic bead-sorted in vivo biotinylated survivin for monoclonal antibody production. J. Immunol. Methods 2006, 317:1-11.
60. Tragoolpua K., Intasai N., Kasinrerk W., Mai S., Yuan Y., Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol. 2008, 8:5.
61. Wang L., Ku X.M., Li Y., Bian H.J., Zhang S.H., Ye H., Yao X.Y., Li B.H., Yang X.M., Liao C.G., Chen Z.N. Regulation of matrix metalloproteinase production and tumor cell invasion by four monoclonal antibodies against different epitopes of HAb18G/CD147 extracellular domain. Hybridoma (Larchmt) 2006, 25:60-67.
62. Wang Q., Li M., Wang Y., Zhang Y., Jin S., Xie G., Liu Z., Wang S., Zhang H., Shen L., Ge H. RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Lett. 2008, 269:127-138.
63. Wheeler Y.Y., Kute T.E., Willingham M.C., Chen S.Y., Sane D.C. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. Faseb J. 2003, 17:1733-1735.
64. Yamaoka T., Yonemitsu Y., Komori K., Baba H., Matsumoto T., Onohara T., Maehara Y. Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1865-H1872.
65. Yan L., Zucker S., Toole B.P. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 2005, 93:199-204.
66. Yang Y., Yang S., Ye Z., Jaffar J., Zhou Y., Cutter E., Lieber A., Hellstrom I., Hellstrom K.E. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res. 2007, 67:2339-2344.
67. Yang Z.M., Li E.M., Lai B.C., Wang Y.L., Si L.S. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity. Biochem. Cell Biol. 2007, 85:196-202.
68. Yu W.H., Woessner J.F. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J. Biol. Chem. 2000, 275:4183-4191.
69. Zdoroveac A., Doebis C., Laube H., Brosel S., Schmitt-Knosalla I., Volk H.D., Seifert M. Modulation of graft arteriosclerosis in a rat carotid transplantation model. J. Surg. Res. 2008, 145:161-169.
70. Zou W., Yang H., Hou X., Zhang W., Chen B., Xin X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett. 2007, 248:211-218.